Related Experiment Video
Updated: Aug 18, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
The emerging role of bisphosphonates in prostate cancer
Edwin M Posadas1, William L Dahut, James Gulley
1Medical Oncology Clinical Research Unit, Laboratory of Tumor Immunology and Biology, Center for Cancer Research National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1750, Building 10, Room 5B52, Bethesda, MD 20892, USA.
Abstract:
Bisphosphonates are a class of therapeutic agents originally designed to treat loss of bone density. It has been shown that the primary mechanism of action is inhibition of osteoclastic activity. Accumulating data show that these drugs are useful in diseases with propensities toward osseous metastases. In particular, they are effective in diseases in which there is clear upregulation of osteoclastic or osteolytic activity such as breast cancer and multiple myeloma. Despite the fact that osseous metastases in prostate cancer manifest as osteosclerosis rather than osteolysis, studies now show that bisphosphonates are useful in the management of this disease. In particular, they have demonstrated an impact on osteoporosis associated with hormonal therapy, bone pain from metastases, and skeleton-related events from prostatic adenocarcinoma. This review briefly summarizes the available clinical data on the utilization of bisphosphonates in the disease of prostate cancer.
Insights
Bisphosphonates inhibit osteoclasts and are effective for bone density loss. They are increasingly used to manage prostate cancer complications like bone pain and osteoporosis from hormonal therapy.
Area of Science:
- Oncology
- Pharmacology
- Bone Metabolism
Background:
- Bisphosphonates are drugs that inhibit osteoclast activity, primarily used for bone density loss.
- They are effective in cancers with osteolytic bone metastases, such as breast cancer and multiple myeloma.
Purpose of the Study:
- To review the clinical data on bisphosphonate utilization in prostate cancer management.
- To highlight the efficacy of bisphosphonates in prostate cancer-associated bone complications.
Main Methods:
- Review of existing clinical data and studies.
- Analysis of bisphosphonate efficacy in prostate cancer patients.
Main Results:
- Bisphosphonates demonstrate utility in prostate cancer, despite osteosclerotic metastases.
- Proven impact on osteoporosis, bone pain, and skeletal-related events in prostate cancer.
Conclusions:
- Bisphosphonates are valuable therapeutic agents for managing bone complications in prostate cancer.
- Clinical data support the use of bisphosphonates in prostate cancer, particularly for hormonal therapy-induced osteoporosis and metastatic bone disease.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:32Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Osteoclasts in Bone Remodeling
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...